
--- Page 1 ---
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
ASSAY ONLY TEMPLATE
A. 510(k) Number:
k140748
B. Purpose for Submission:
New device
C. Measurand:
Buprenorphine, EDDP (2-ethylidene-1, 5-dimethyl-3, 3-diphenylpyrrolidine), Morphine,
Propoxyphene, and Tricyclic Antidepressants
D. Type of Test:
Qualitative lateral flow immunochromatographic competitive binding assay
E. Applicant:
Co-Innovation Biotech Co., Ltd.
F. Proprietary and Established Names:
One Step Single/Multi-drug Test Cup
One Step Single/Multi-drug Test Dipcard
G. Regulatory Information:
1. Regulation section:
Product
Classification Regulation Section Panel
Code
DJG Class II 862.3650 Opiate test system Toxicology (91)
DJR Class II 862.3620 Methadone test system Toxicology (91)
DNK Class II 862.3640 Morphine test system Toxicology (91)
JXN Class II 862.3700 Propoxyphene test system Toxicology (91)
862.3910 Tricyclic antidepressant
LFG Class II Toxicology (91)
drugs test system
1

[Table 1 on page 1]
	Product		Classification	Regulation Section	Panel
	Code				
DJG			Class II	862.3650 Opiate test system	Toxicology (91)
DJR			Class II	862.3620 Methadone test system	Toxicology (91)
DNK			Class II	862.3640 Morphine test system	Toxicology (91)
JXN			Class II	862.3700 Propoxyphene test system	Toxicology (91)
LFG			Class II	862.3910 Tricyclic antidepressant
drugs test system	Toxicology (91)

--- Page 2 ---
H. Intended Use:
1. Intended use(s):
Refer to Indications for Use below.
2. Indication(s) for use:
One Step Single/Multi-drug Test Cup and One Step Single/Multi-drug Test Dipcard are
lateral flow chromatographic immunoassays designed to qualitatively detect the presence
of drugs and drug metabolites in human urine at the following cut-off concentrations:
Cutoff Level
Test Calibrator
(ng/mL)
Buprenorphine (BUP) Buprenorphine 10
2-ethylidene-1, 5-dimethyl-3, 2-ethylidene-1, 5-dimethyl-3,
300
3-diphenylpyrrolidine (EDDP) 3-diphenylpyrrolidine
Morphine (MOP300) Morphine 300
Propoxyphene (PPX) Propoxyphene 300
Tri-cyclic Antidepressants
Nortriptyline 1000
(TCA)
There are two formats: 1) Test Cup, 2) Test Dipcard. Each format may have from 1 to 5
drugs in any combination. The assays are intended for in vitro diagnostic use. They are
intended for prescription use including point of care sites and over-the-counter use.
The tests may yield preliminary positive results even when prescription drugs including
Buprenorphine, Propoxyphene, or Tricyclic Antidepressants are ingested, at prescribed
doses; it is not intended to distinguish between prescription use or abuse of these drugs.
There are no uniformly recognized cutoff concentration levels for Buprenorphine,
Propoxyphene, or Tricyclic Antidepressant in urine.
This assay provides only a preliminary analytical test result. Gas Chromatography/Mass
spectrometry (GC/MS) or an equivalent analytical method is the preferred confirmatory
method. Clinical consideration and professional judgment should be applied to any drug
of abuse test result, particularly when preliminary positive results are indicated.
2

[Table 1 on page 2]
Test	Calibrator	Cutoff Level
(ng/mL)
Buprenorphine (BUP)	Buprenorphine	10
2-ethylidene-1, 5-dimethyl-3,
3-diphenylpyrrolidine (EDDP)	2-ethylidene-1, 5-dimethyl-3,
3-diphenylpyrrolidine	300
Morphine (MOP300)	Morphine	300
Propoxyphene (PPX)	Propoxyphene	300
Tri-cyclic Antidepressants
(TCA)	Nortriptyline	1000

[Table 2 on page 2]
Cutoff Level
(ng/mL)

--- Page 3 ---
3. Special conditions for use statement(s):
These assays are intended for prescription use, including point of care and over the
counter use.
4. Special instrument requirements:
Not applicable; these are visually read single use devices.
I. Device Description:
One Step Single/Multi-drug Test Cup and One Step Single/Multi-drug Test Dipcard are
competitive binding, lateral flow immunochromatographic assays for the qualitative
detection of Buprenorphine, 2-ethylidene-1, 5-dimethyl-3, 3-diphenylpyrrolidine, Morphine,
Propoxyphene, Tricyclic Antidepressants and their metabolites at or above the cut-off levels
as indicated. The devices are available in both a test cup and a test card format. The test
configuration comes with single drug screening test or any combinations of multiple drug
screening tests. The tests are visually read.
J. Substantial Equivalence Information:
1. Predicate device name(s):
Advin Multi-Drug Screen Test Dip Card
Advin Multi-Drug Screen Test Cup
Advin Multi-Drug Screen Test Cassette
2. Predicate 510(k) number(s):
k122809
3. Comparison with predicate:
Similarities
Item Candidate Device Predicate Device (k122809)
Matrix Same Urine
Buprenorphine: 10 ng/mL
EDDP: 300 ng/mL
Cutoffs Same Morphine: 300 ng/mL
Propoxyphene: 300 ng/mL
TCA: 1000 ng/mL
Read time Same Five minutes
3

[Table 1 on page 3]
Similarities								
	Item			Candidate Device			Predicate Device (k122809)	
Matrix			Same			Urine		
Cutoffs			Same			Buprenorphine: 10 ng/mL
EDDP: 300 ng/mL
Morphine: 300 ng/mL
Propoxyphene: 300 ng/mL
TCA: 1000 ng/mL		
Read time			Same			Five minutes		

--- Page 4 ---
Competitive binding, Lateral
Methodology Same flow immunochromatographic
assay
Results Same Qualitative
Layusers (OTC) and healthcare
Intended Users Same professionals (prescription point
of care)
Differences
Predicate Device
Item Candidate Device
(k122809)
Available formats Dipcard and Cup Cassette, Dip Card and Cup
Number of
Five Sixteen
analytes detected
K. Standard/Guidance Document Referenced (if applicable):
EN13612:2002 Stability testing of in vitro diagnostic reagents
L. Test Principle:
One Step Single/Multi-drug Test Cup and Dip Card are competitive immunoassays used to
screen for the presence of various drugs and drug metabolites in urine. They are
chromatographic absorbent devices in which drugs or metabolites in a urine sample
competitively combine with a limited number of drug monoclonal antibody (mouse)
conjugate binding sites.
When the test is activated, the urine is absorbed into each test strip by capillary action, mixes
with the respective analyte monoclonal antibody conjugate, and flows across a pre-coated
membrane. When drug within the urine sample is at a level below the cutoff of the test, the
drug monoclonal antibody conjugate binds to the corresponding drug-protein conjugate
immobilized in the Test Region (T) of the test strip. This produces a colored Test line in the
Test Region (T) of the strip that, regardless of its intensity, indicates a negative test result.
When sample drug levels are at or above the cutoff of the test, the free drug in the sample
binds to the corresponding drug monoclonal antibody conjugate, preventing the respective
drug monoclonal antibody conjugate from binding to the corresponding drug-protein
conjugate immobilized in the Test Region (T) of the device. This prevents the development
of a distinct colored band in the test region, indicating a preliminary positive result.
To serve as a procedure control, a colored line will appear at the Control Region (C) of each
strip if the volume of sample applied is adequate and the test is operating properly.
4

[Table 1 on page 4]
Methodology	Same	Competitive binding, Lateral
flow immunochromatographic
assay
Results	Same	Qualitative
Intended Users	Same	Layusers (OTC) and healthcare
professionals (prescription point
of care)

[Table 2 on page 4]
Differences				
Item	Candidate Device		Predicate Device	
			(k122809)	
Available formats	Dipcard and Cup	Cassette, Dip Card and Cup		
Number of
analytes detected	Five	Sixteen		

--- Page 5 ---
M. Performance Characteristics (if/when applicable):
1. Analytical performance:
a. Precision/Reproducibility:
Drug free specimens were spiked with the analytes at 0%, -75%, -50%, -25%, cutoff,
+25%, +50%, +75%, and +100% of the cutoff. All concentrations were confirmed
with GC/MS, LC/MS, or HPLC. Urine specimens at each concentration were divided
into aliquots. All aliquots were blindly labeled by a nonparticipant. Separate sets of
the blind coded samples were assigned and randomized prior to testing. The study
was conducted by three nurses at three Point-of-Care sites.
Buprenorphine - Dipcard Format – Multi
Conc % of Lot 1 Lot 2 Lot 3
(ng/mL) cutoff Pos Neg Pos Neg Pos Neg
0 Neg 0 60 0 60 0 60
2.5 -75 0 60 0 60 0 60
5 -50 0 60 0 60 0 60
7.5 -25 10 50 12 48 8 52
10 Cutoff 38 22 36 24 34 26
12.5 +25 54 6 50 10 52 8
15 +50 56 4 58 2 56 4
17.5 +75 60 0 60 0 60 0
20 +100 60 0 60 0 60 0
Buprenorphine - Dipcard Format – Single
Conc % of Lot 1 Lot 2 Lot 3
(ng/mL) cutoff Pos Neg Pos Neg Pos Neg
0 Neg 0 60 0 60 0 60
2.5 -75 0 60 0 60 0 60
5 -50 0 60 0 60 0 60
7.5 -25 12 48 8 52 10 50
10 Cutoff 34 26 36 24 34 26
12.5 +25 50 10 48 12 50 10
15 +50 54 6 56 4 56 4
17.5 +75 60 0 60 0 60 0
20 +100 60 0 60 0 60 0
5

[Table 1 on page 5]
Conc
(ng/mL)	% of
cutoff	Lot 1		Lot 2		Lot 3	
		Pos	Neg	Pos	Neg	Pos	Neg
0	Neg	0	60	0	60	0	60
2.5	-75	0	60	0	60	0	60
5	-50	0	60	0	60	0	60
7.5	-25	10	50	12	48	8	52
10	Cutoff	38	22	36	24	34	26
12.5	+25	54	6	50	10	52	8
15	+50	56	4	58	2	56	4
17.5	+75	60	0	60	0	60	0
20	+100	60	0	60	0	60	0

[Table 2 on page 5]
Conc
(ng/mL)	% of
cutoff	Lot 1		Lot 2		Lot 3	
		Pos	Neg	Pos	Neg	Pos	Neg
0	Neg	0	60	0	60	0	60
2.5	-75	0	60	0	60	0	60
5	-50	0	60	0	60	0	60
7.5	-25	12	48	8	52	10	50
10	Cutoff	34	26	36	24	34	26
12.5	+25	50	10	48	12	50	10
15	+50	54	6	56	4	56	4
17.5	+75	60	0	60	0	60	0
20	+100	60	0	60	0	60	0

--- Page 6 ---
Buprenorphine - Cup Format – Multi
Conc % of Lot 1 Lot 2 Lot 3
(ng/mL) cutoff Pos Neg Pos Neg Pos Neg
0 Neg 0 60 0 60 0 60
2.5 -75 0 60 0 60 0 60
5 -50 0 60 0 60 0 60
7.5 -25 10 50 8 52 6 54
10 Cutoff 34 26 32 28 36 24
12.5 +25 54 6 56 4 52 8
15 +50 60 0 58 2 56 4
17.5 +75 60 0 60 0 60 0
20 +100 60 0 60 0 60 0
Buprenorphine - Cup Format – Single
Conc % of Lot 1 Lot 2 Lot 3
(ng/mL) cutoff Pos Neg Pos Neg Pos Neg
0 Neg 0 60 0 60 0 60
0 -75 0 60 0 60 0 60
2.5 -50 0 60 0 60 0 60
5 -25 6 54 8 52 10 50
7.5 Cutoff 32 28 36 24 34 26
10 +25 52 8 50 10 54 6
12.5 +50 58 2 60 0 56 4
15 +75 60 0 60 0 60 0
17.5 +100 60 0 60 0 60 0
EDDP – Dipcard Format – Multi
Conc % of Lot 1 Lot 2 Lot 3
(ng/mL) cutoff Pos Neg Pos Neg Pos Neg
0 Neg 0 60 0 60 0 60
75 -75 0 60 0 60 0 60
150 -50 0 60 0 60 0 60
225 -25 10 50 8 52 6 54
300 Cutoff 32 28 36 24 34 26
375 +25 54 6 52 8 50 10
450 +50 60 0 58 2 56 4
525 +75 60 0 60 0 60 0
600 +100 60 0 60 0 60 0
6

[Table 1 on page 6]
Conc
(ng/mL)	% of
cutoff	Lot 1		Lot 2		Lot 3	
		Pos	Neg	Pos	Neg	Pos	Neg
0	Neg	0	60	0	60	0	60
2.5	-75	0	60	0	60	0	60
5	-50	0	60	0	60	0	60
7.5	-25	10	50	8	52	6	54
10	Cutoff	34	26	32	28	36	24
12.5	+25	54	6	56	4	52	8
15	+50	60	0	58	2	56	4
17.5	+75	60	0	60	0	60	0
20	+100	60	0	60	0	60	0

[Table 2 on page 6]
Conc
(ng/mL)	% of
cutoff	Lot 1		Lot 2		Lot 3	
		Pos	Neg	Pos	Neg	Pos	Neg
0	Neg	0	60	0	60	0	60
0	-75	0	60	0	60	0	60
2.5	-50	0	60	0	60	0	60
5	-25	6	54	8	52	10	50
7.5	Cutoff	32	28	36	24	34	26
10	+25	52	8	50	10	54	6
12.5	+50	58	2	60	0	56	4
15	+75	60	0	60	0	60	0
17.5	+100	60	0	60	0	60	0

[Table 3 on page 6]
Conc
(ng/mL)	% of
cutoff	Lot 1		Lot 2		Lot 3	
		Pos	Neg	Pos	Neg	Pos	Neg
0	Neg	0	60	0	60	0	60
75	-75	0	60	0	60	0	60
150	-50	0	60	0	60	0	60
225	-25	10	50	8	52	6	54
300	Cutoff	32	28	36	24	34	26
375	+25	54	6	52	8	50	10
450	+50	60	0	58	2	56	4
525	+75	60	0	60	0	60	0
600	+100	60	0	60	0	60	0

--- Page 7 ---
EDDP – Dipcard Format – Single
Conc % of Lot 1 Lot 2 Lot 3
(ng/mL) cutoff Pos Neg Pos Neg Pos Neg
0 Neg 0 60 0 60 0 60
75 -75 0 60 0 60 0 60
150 -50 0 60 0 60 0 60
225 -25 10 50 6 54 8 52
300 Cutoff 38 22 36 24 32 28
375 +25 50 10 48 12 52 8
450 +50 56 4 60 0 58 2
525 +75 60 0 60 0 60 0
600 +100 60 0 60 0 60 0
EDDP – Cup Format – Multi
Conc % of
Lot 1 Lot 2 Lot 3
(ng/mL) cutoff
Pos Neg Pos Neg Pos Neg
0 Neg 0 60 0 60 0 60
75 -75 0 60 0 60 0 60
150 -50 0 60 0 60 0 60
225 -25 10 50 8 52 12 48
300 Cutoff 36 24 38 22 34 26
375 +25 56 4 54 6 52 8
450 +50 58 2 56 4 58 2
525 +75 60 0 60 0 60 0
600 +100 60 0 60 0 60 0
EDDP – Cup Format – Single
Conc % of
Lot 1 Lot 2 Lot 3
(ng/mL) cutoff
Pos Neg Pos Neg Pos Neg
0 Neg 0 60 0 60 0 60
75 -75 0 60 0 60 0 60
150 -50 0 60 0 60 0 60
225 -25 8 52 6 54 10 50
300 Cutoff 34 26 36 24 32 28
375 +25 52 8 54 6 50 10
450 +50 60 0 56 4 58 2
525 +75 60 0 60 0 60 0
600 +100 60 0 60 0 60 0
7

[Table 1 on page 7]
Conc
(ng/mL)	% of
cutoff	Lot 1		Lot 2		Lot 3	
		Pos	Neg	Pos	Neg	Pos	Neg
0	Neg	0	60	0	60	0	60
75	-75	0	60	0	60	0	60
150	-50	0	60	0	60	0	60
225	-25	10	50	6	54	8	52
300	Cutoff	38	22	36	24	32	28
375	+25	50	10	48	12	52	8
450	+50	56	4	60	0	58	2
525	+75	60	0	60	0	60	0
600	+100	60	0	60	0	60	0

[Table 2 on page 7]
Conc
(ng/mL)	% of
cutoff	Lot 1		Lot 2		Lot 3	
		Pos	Neg	Pos	Neg	Pos	Neg
0	Neg	0	60	0	60	0	60
75	-75	0	60	0	60	0	60
150	-50	0	60	0	60	0	60
225	-25	10	50	8	52	12	48
300	Cutoff	36	24	38	22	34	26
375	+25	56	4	54	6	52	8
450	+50	58	2	56	4	58	2
525	+75	60	0	60	0	60	0
600	+100	60	0	60	0	60	0

[Table 3 on page 7]
Conc
(ng/mL)	% of
cutoff	Lot 1		Lot 2		Lot 3	
		Pos	Neg	Pos	Neg	Pos	Neg
0	Neg	0	60	0	60	0	60
75	-75	0	60	0	60	0	60
150	-50	0	60	0	60	0	60
225	-25	8	52	6	54	10	50
300	Cutoff	34	26	36	24	32	28
375	+25	52	8	54	6	50	10
450	+50	60	0	56	4	58	2
525	+75	60	0	60	0	60	0
600	+100	60	0	60	0	60	0

--- Page 8 ---
Morphine – Dipcard Format – Multi
Conc % of Lot 1 Lot 2 Lot 3
(ng/mL) cutoff Pos Neg Pos Neg Pos Neg
0 Neg 0 60 0 60 0 60
75 -75 0 60 0 60 0 60
150 -50 0 60 0 60 0 60
225 -25 6 54 4 56 8 52
300 Cutoff 36 24 38 22 34 26
375 +25 50 10 48 12 52 8
450 +50 56 4 58 2 60 0
525 +75 60 0 60 0 60 0
600 +100 60 0 60 0 60 0
Morphine – Dipcard Format – Single
Conc % of Lot 1 Lot 2 Lot 3
(ng/mL) cutoff Pos Neg Pos Neg Pos Neg
0 Neg 0 60 0 60 0 60
75 -75 0 60 0 60 0 60
150 -50 0 60 0 60 0 60
225 -25 8 52 12 48 10 50
300 Cutoff 36 24 34 26 38 22
375 +25 54 6 56 4 52 8
450 +50 58 2 60 0 56 4
525 +75 60 0 60 0 60 0
600 +100 60 0 60 0 60 0
Morphine – Cup Format – Multi
Conc % of Lot 1 Lot 2 Lot 3
(ng/mL) cutoff Pos Neg Pos Neg Pos Neg
0 Neg 0 60 0 60 0 60
75 -75 0 60 0 60 0 60
150 -50 0 60 0 60 0 60
225 -25 8 52 6 54 4 56
300 Cutoff 34 26 36 24 38 22
375 +25 54 6 50 10 52 8
450 +50 58 2 60 0 56 4
525 +75 60 0 60 0 60 0
600 +100 60 0 60 0 60 0
8

[Table 1 on page 8]
Conc
(ng/mL)	% of
cutoff	Lot 1		Lot 2		Lot 3	
		Pos	Neg	Pos	Neg	Pos	Neg
0	Neg	0	60	0	60	0	60
75	-75	0	60	0	60	0	60
150	-50	0	60	0	60	0	60
225	-25	6	54	4	56	8	52
300	Cutoff	36	24	38	22	34	26
375	+25	50	10	48	12	52	8
450	+50	56	4	58	2	60	0
525	+75	60	0	60	0	60	0
600	+100	60	0	60	0	60	0

[Table 2 on page 8]
Conc
(ng/mL)	% of
cutoff	Lot 1		Lot 2		Lot 3	
		Pos	Neg	Pos	Neg	Pos	Neg
0	Neg	0	60	0	60	0	60
75	-75	0	60	0	60	0	60
150	-50	0	60	0	60	0	60
225	-25	8	52	12	48	10	50
300	Cutoff	36	24	34	26	38	22
375	+25	54	6	56	4	52	8
450	+50	58	2	60	0	56	4
525	+75	60	0	60	0	60	0
600	+100	60	0	60	0	60	0

[Table 3 on page 8]
Conc
(ng/mL)	% of
cutoff	Lot 1		Lot 2		Lot 3	
		Pos	Neg	Pos	Neg	Pos	Neg
0	Neg	0	60	0	60	0	60
75	-75	0	60	0	60	0	60
150	-50	0	60	0	60	0	60
225	-25	8	52	6	54	4	56
300	Cutoff	34	26	36	24	38	22
375	+25	54	6	50	10	52	8
450	+50	58	2	60	0	56	4
525	+75	60	0	60	0	60	0
600	+100	60	0	60	0	60	0

--- Page 9 ---
Morphine – Cup Format – Single
Conc % of Lot 1 Lot 2 Lot 3
(ng/mL) cutoff Pos Neg Pos Neg Pos Neg
0 Neg 0 60 0 60 0 60
75 -75 0 60 0 60 0 60
150 -50 0 60 0 60 0 60
225 -25 6 54 8 52 4 56
300 Cutoff 34 26 38 22 36 24
375 +25 48 12 50 10 52 8
450 +50 60 0 58 2 56 4
525 +75 60 0 60 0 60 0
600 +100 60 0 60 0 60 0
Propoxyphene – Dipcard Format – Multi
Conc % of Lot 1 Lot 2 Lot 3
(ng/mL) cutoff Pos Neg Pos Neg Pos Neg
0 Neg 0 60 0 60 0 60
75 -75 0 60 0 60 0 60
150 -50 0 60 0 60 0 60
225 -25 4 56 8 52 6 54
300 Cutoff 36 24 34 26 38 22
375 +25 48 12 52 8 50 10
450 +50 56 4 58 2 58 2
525 +75 60 0 60 0 60 0
600 +100 60 0 60 0 60 0
Propoxyphene – Dipcard Format – Single
Conc % of Lot 1 Lot 2 Lot 3
(ng/mL) cutoff Pos Neg Pos Neg Pos Neg
0 Neg 0 60 0 60 0 60
75 -75 0 60 0 60 0 60
150 -50 0 60 0 60 0 60
225 -25 6 54 8 52 10 50
300 Cutoff 38 22 34 26 32 28
375 +25 52 8 54 6 50 10
450 +50 56 4 58 2 60 0
525 +75 60 0 60 0 60 0
600 +100 60 0 60 0 60 0
9

[Table 1 on page 9]
Conc
(ng/mL)	% of
cutoff	Lot 1		Lot 2		Lot 3	
		Pos	Neg	Pos	Neg	Pos	Neg
0	Neg	0	60	0	60	0	60
75	-75	0	60	0	60	0	60
150	-50	0	60	0	60	0	60
225	-25	6	54	8	52	4	56
300	Cutoff	34	26	38	22	36	24
375	+25	48	12	50	10	52	8
450	+50	60	0	58	2	56	4
525	+75	60	0	60	0	60	0
600	+100	60	0	60	0	60	0

[Table 2 on page 9]
Conc
(ng/mL)	% of
cutoff	Lot 1		Lot 2		Lot 3	
		Pos	Neg	Pos	Neg	Pos	Neg
0	Neg	0	60	0	60	0	60
75	-75	0	60	0	60	0	60
150	-50	0	60	0	60	0	60
225	-25	4	56	8	52	6	54
300	Cutoff	36	24	34	26	38	22
375	+25	48	12	52	8	50	10
450	+50	56	4	58	2	58	2
525	+75	60	0	60	0	60	0
600	+100	60	0	60	0	60	0

[Table 3 on page 9]
Conc
(ng/mL)	% of
cutoff	Lot 1		Lot 2		Lot 3	
		Pos	Neg	Pos	Neg	Pos	Neg
0	Neg	0	60	0	60	0	60
75	-75	0	60	0	60	0	60
150	-50	0	60	0	60	0	60
225	-25	6	54	8	52	10	50
300	Cutoff	38	22	34	26	32	28
375	+25	52	8	54	6	50	10
450	+50	56	4	58	2	60	0
525	+75	60	0	60	0	60	0
600	+100	60	0	60	0	60	0

--- Page 10 ---
Propoxyphene – Cup Format – Multi
Conc % of Lot 1 Lot 2 Lot 3
(ng/mL) cutoff Pos Neg Pos Neg Pos Neg
0 Neg 0 60 0 60 0 60
75 -75 0 60 0 60 0 60
150 -50 0 60 0 60 0 60
225 -25 6 54 8 52 6 54
300 Cutoff 34 26 38 22 36 24
375 +25 56 4 52 8 54 6
450 +50 60 0 58 2 50 0
525 +75 60 0 60 0 60 0
600 +100 60 0 60 0 60 0
Propoxyphene – Cup Format – Single
Conc % of Lot 1 Lot 2 Lot 3
(ng/mL) cutoff Pos Neg Pos Neg Pos Neg
0 Neg 0 60 0 60 0 60
75 -75 0 60 0 60 0 60
150 -50 0 60 0 60 0 60
225 -25 8 52 6 54 4 56
300 Cutoff 38 22 34 26 36 24
375 +25 54 6 50 10 52 8
450 +50 60 0 56 4 58 2
525 +75 60 0 60 0 60 0
600 +100 60 0 60 0 60 0
TCA – Dipcard Format – Multi
Conc % of Lot 1 Lot 2 Lot 3
(ng/mL) cutoff Pos Neg Pos Neg Pos Neg
0 Neg 0 60 0 60 0 60
250 -75 0 60 0 60 0 60
500 -50 0 60 0 60 0 60
750 -25 4 56 6 54 4 56
1000 Cutoff 36 24 38 22 34 26
1250 +25 54 6 56 4 52 8
1500 +50 58 2 60 0 56 4
1750 +75 60 0 60 0 60 0
2000 +100 60 0 60 0 60 0
10

[Table 1 on page 10]
Conc
(ng/mL)	% of
cutoff	Lot 1		Lot 2		Lot 3	
		Pos	Neg	Pos	Neg	Pos	Neg
0	Neg	0	60	0	60	0	60
75	-75	0	60	0	60	0	60
150	-50	0	60	0	60	0	60
225	-25	6	54	8	52	6	54
300	Cutoff	34	26	38	22	36	24
375	+25	56	4	52	8	54	6
450	+50	60	0	58	2	50	0
525	+75	60	0	60	0	60	0
600	+100	60	0	60	0	60	0

[Table 2 on page 10]
Conc
(ng/mL)	% of
cutoff	Lot 1		Lot 2		Lot 3	
		Pos	Neg	Pos	Neg	Pos	Neg
0	Neg	0	60	0	60	0	60
75	-75	0	60	0	60	0	60
150	-50	0	60	0	60	0	60
225	-25	8	52	6	54	4	56
300	Cutoff	38	22	34	26	36	24
375	+25	54	6	50	10	52	8
450	+50	60	0	56	4	58	2
525	+75	60	0	60	0	60	0
600	+100	60	0	60	0	60	0

[Table 3 on page 10]
Conc
(ng/mL)	% of
cutoff	Lot 1		Lot 2		Lot 3	
		Pos	Neg	Pos	Neg	Pos	Neg
0	Neg	0	60	0	60	0	60
250	-75	0	60	0	60	0	60
500	-50	0	60	0	60	0	60
750	-25	4	56	6	54	4	56
1000	Cutoff	36	24	38	22	34	26
1250	+25	54	6	56	4	52	8
1500	+50	58	2	60	0	56	4
1750	+75	60	0	60	0	60	0
2000	+100	60	0	60	0	60	0

--- Page 11 ---
TCA – Dipcard Format – Single
Conc % of Lot 1 Lot 2 Lot 3
(ng/mL) cutoff Pos Neg Pos Neg Pos Neg
0 Neg 0 60 0 60 0 60
250 -75 0 60 0 60 0 60
500 -50 0 60 0 60 0 60
750 -25 8 52 6 54 10 50
1000 Cutoff 34 26 35 24 32 28
1250 +25 50 10 52 8 50 10
1500 +50 60 0 56 4 58 2
1750 +75 60 0 60 0 60 0
2000 +100 60 0 60 0 60 0
TCA – Cup Format – Multi
Conc % of Lot 1 Lot 2 Lot 3
(ng/mL) cutoff Pos Neg Pos Neg Pos Neg
0 Neg 0 60 0 60 0 60
250 -75 0 60 0 60 0 60
500 -50 0 60 0 60 0 60
750 -25 8 52 4 56 6 54
1000 Cutoff 34 26 38 22 36 24
1250 +25 50 10 48 12 52 8
1500 +50 56 4 60 0 58 2
1750 +75 60 0 60 0 60 0
2000 +100 60 0 60 0 60 0
TCA – Cup Format – Single
Conc % of Lot 1 Lot 2 Lot 3
(ng/mL) cutoff Pos Neg Pos Neg Pos Neg
0 Neg 0 60 0 60 0 60
250 -75 0 60 0 60 0 60
500 -50 0 60 0 60 0 60
750 -25 4 56 8 52 6 54
1000 Cutoff 38 22 34 26 36 24
1250 +25 52 8 48 12 50 10
1500 +50 58 2 58 2 56 4
1750 +75 60 0 60 0 60 0
2000 +100 60 0 60 0 60 0
The original precision study data showed numerous negative results in the specimens
containing drug concentrations at +50% above the cutoff. A root cause analysis was
conducted by the sponsor to determine the cause of these results. The root cause was
identified to be inconsistent and inadequate volume of aliquoted samples. The
sponsor revised the precision study protocol to specify a sample volume per vial and
supplemental precision studies were conducted to verify that the root cause was
11

[Table 1 on page 11]
Conc
(ng/mL)	% of
cutoff	Lot 1		Lot 2		Lot 3	
		Pos	Neg	Pos	Neg	Pos	Neg
0	Neg	0	60	0	60	0	60
250	-75	0	60	0	60	0	60
500	-50	0	60	0	60	0	60
750	-25	8	52	6	54	10	50
1000	Cutoff	34	26	35	24	32	28
1250	+25	50	10	52	8	50	10
1500	+50	60	0	56	4	58	2
1750	+75	60	0	60	0	60	0
2000	+100	60	0	60	0	60	0

[Table 2 on page 11]
Conc
(ng/mL)	% of
cutoff	Lot 1		Lot 2		Lot 3	
		Pos	Neg	Pos	Neg	Pos	Neg
0	Neg	0	60	0	60	0	60
250	-75	0	60	0	60	0	60
500	-50	0	60	0	60	0	60
750	-25	8	52	4	56	6	54
1000	Cutoff	34	26	38	22	36	24
1250	+25	50	10	48	12	52	8
1500	+50	56	4	60	0	58	2
1750	+75	60	0	60	0	60	0
2000	+100	60	0	60	0	60	0

[Table 3 on page 11]
Conc
(ng/mL)	% of
cutoff	Lot 1		Lot 2		Lot 3	
		Pos	Neg	Pos	Neg	Pos	Neg
0	Neg	0	60	0	60	0	60
250	-75	0	60	0	60	0	60
500	-50	0	60	0	60	0	60
750	-25	4	56	8	52	6	54
1000	Cutoff	38	22	34	26	36	24
1250	+25	52	8	48	12	50	10
1500	+50	58	2	58	2	56	4
1750	+75	60	0	60	0	60	0
2000	+100	60	0	60	0	60	0

--- Page 12 ---
correctly identified.
Supplemental precision studies were conducted for the single drug and multi-drug test
formats using drug free urine specimens spiked at analyte concentrations of 0%,
-75%, -50%, -25%, cutoff, +25%, +50%, +75%, and +100% of the cutoff. All
concentrations were confirmed with GC/MS, LC/MS, or HPLC. Urine specimens at
each concentration were divided into aliquots. All aliquots were blindly labeled by a
nonparticipant. Separate sets of the blind coded samples were assigned and
randomized prior to testing. The study was conducted by three nurses at three Point-
of-Care sites.
Buprenorphine - Dipcard Format – Multi
Conc % of Lot 1 Lot 2 Lot 3
(ng/mL) cutoff Pos Neg Pos Neg Pos Neg
0 Neg 0 60 0 60 0 60
2.5 -75 0 60 0 60 0 60
5 -50 0 60 0 60 0 60
7.5 -25 8 52 4 56 6 54
10 Cutoff 34 26 32 28 36 24
12.5 +25 56 4 54 6 52 8
15 +50 60 0 60 0 60 0
17.5 +75 60 0 60 0 60 0
20 +100 60 0 60 0 60 0
Buprenorphine - Dipcard Format – Single
Conc % of Lot 1 Lot 2 Lot 3
(ng/mL) cutoff Pos Neg Pos Neg Pos Neg
0 Neg 0 60 0 60 0 60
2.5 -75 0 60 0 60 0 60
5 -50 0 60 0 60 0 60
7.5 -25 4 56 8 52 6 54
10 Cutoff 34 26 36 24 38 22
12.5 +25 56 4 52 8 54 6
15 +50 60 0 60 0 60 0
17.5 +75 60 0 60 0 60 0
20 +100 60 0 60 0 60 0
12

[Table 1 on page 12]
Conc
(ng/mL)	% of
cutoff	Lot 1		Lot 2		Lot 3	
		Pos	Neg	Pos	Neg	Pos	Neg
0	Neg	0	60	0	60	0	60
2.5	-75	0	60	0	60	0	60
5	-50	0	60	0	60	0	60
7.5	-25	8	52	4	56	6	54
10	Cutoff	34	26	32	28	36	24
12.5	+25	56	4	54	6	52	8
15	+50	60	0	60	0	60	0
17.5	+75	60	0	60	0	60	0
20	+100	60	0	60	0	60	0

[Table 2 on page 12]
Conc
(ng/mL)	% of
cutoff	Lot 1		Lot 2		Lot 3	
		Pos	Neg	Pos	Neg	Pos	Neg
0	Neg	0	60	0	60	0	60
2.5	-75	0	60	0	60	0	60
5	-50	0	60	0	60	0	60
7.5	-25	4	56	8	52	6	54
10	Cutoff	34	26	36	24	38	22
12.5	+25	56	4	52	8	54	6
15	+50	60	0	60	0	60	0
17.5	+75	60	0	60	0	60	0
20	+100	60	0	60	0	60	0

--- Page 13 ---
Buprenorphine - Cup Format – Multi
Conc % of Lot 1 Lot 2 Lot 3
(ng/mL) cutoff Pos Neg Pos Neg Pos Neg
0 Neg 0 60 0 60 0 60
2.5 -75 0 60 0 60 0 60
5 -50 0 60 0 60 0 60
7.5 -25 6 54 4 56 8 52
10 Cutoff 32 28 34 26 36 24
12.5 +25 54 6 52 8 56 4
15 +50 60 0 60 0 60 0
17.5 +75 60 0 60 0 60 0
20 +100 60 0 60 0 60 0
Buprenorphine - Cup Format – Single
Conc % of Lot 1 Lot 2 Lot 3
(ng/mL) cutoff Pos Neg Pos Neg Pos Neg
0 Neg 0 60 0 60 0 60
0 -75 0 60 0 60 0 60
2.5 -50 0 60 0 60 0 60
5 -25 6 54 8 52 4 56
7.5 Cutoff 32 28 36 24 34 26
10 +25 52 8 54 6 56 4
12.5 +50 60 0 60 0 60 0
15 +75 60 0 60 0 60 0
17.5 +100 60 0 60 0 60 0
EDDP – Dipcard Format – Multi
Conc % of Lot 1 Lot 2 Lot 3
(ng/mL) cutoff Pos Neg Pos Neg Pos Neg
0 Neg 0 60 0 60 0 60
75 -75 0 60 0 60 0 60
150 -50 0 60 0 60 0 60
225 -25 4 56 6 54 8 52
300 Cutoff 36 24 38 22 34 26
375 +25 54 6 52 8 56 4
450 +50 60 0 60 0 60 0
525 +75 60 0 60 0 60 0
600 +100 60 0 60 0 60 0
13

[Table 1 on page 13]
Conc
(ng/mL)	% of
cutoff	Lot 1		Lot 2		Lot 3	
		Pos	Neg	Pos	Neg	Pos	Neg
							
0	Neg	0	60	0	60	0	60
2.5	-75	0	60	0	60	0	60
5	-50	0	60	0	60	0	60
7.5	-25	6	54	4	56	8	52
10	Cutoff	32	28	34	26	36	24
12.5	+25	54	6	52	8	56	4
15	+50	60	0	60	0	60	0
17.5	+75	60	0	60	0	60	0
20	+100	60	0	60	0	60	0

[Table 2 on page 13]
Conc
(ng/mL)	% of
cutoff	Lot 1		Lot 2		Lot 3	
		Pos	Neg	Pos	Neg	Pos	Neg
0	Neg	0	60	0	60	0	60
0	-75	0	60	0	60	0	60
2.5	-50	0	60	0	60	0	60
5	-25	6	54	8	52	4	56
7.5	Cutoff	32	28	36	24	34	26
10	+25	52	8	54	6	56	4
12.5	+50	60	0	60	0	60	0
15	+75	60	0	60	0	60	0
17.5	+100	60	0	60	0	60	0

[Table 3 on page 13]
Conc
(ng/mL)	% of
cutoff	Lot 1		Lot 2		Lot 3	
		Pos	Neg	Pos	Neg	Pos	Neg
0	Neg	0	60	0	60	0	60
75	-75	0	60	0	60	0	60
150	-50	0	60	0	60	0	60
225	-25	4	56	6	54	8	52
300	Cutoff	36	24	38	22	34	26
375	+25	54	6	52	8	56	4
450	+50	60	0	60	0	60	0
525	+75	60	0	60	0	60	0
600	+100	60	0	60	0	60	0

--- Page 14 ---
EDDP – Dipcard Format – Single
Conc % of Lot 1 Lot 2 Lot 3
(ng/mL) cutoff Pos Neg Pos Neg Pos Neg
0 Neg 0 60 0 60 0 60
75 -75 0 60 0 60 0 60
150 -50 0 60 0 60 0 60
225 -25 8 52 4 56 6 54
300 Cutoff 36 24 38 22 34 26
375 +25 56 4 52 8 54 6
450 +50 60 0 60 0 60 0
525 +75 60 0 60 0 60 0
600 +100 60 0 60 0 60 0
EDDP – Cup Format – Multi
Conc % of
Lot 1 Lot 2 Lot 3
(ng/mL) cutoff
Pos Neg Pos Neg Pos Neg
0 Neg 0 60 0 60 0 60
75 -75 0 60 0 60 0 60
150 -50 0 60 0 60 0 60
225 -25 4 56 8 52 6 54
300 Cutoff 36 24 34 26 38 22
375 +25 56 4 52 8 54 6
450 +50 60 0 60 0 60 0
525 +75 60 0 60 0 60 0
600 +100 60 0 60 0 60 0
EDDP – Cup Format – Single
Conc % of
Lot 1 Lot 2 Lot 3
(ng/mL) cutoff
Pos Neg Pos Neg Pos Neg
0 Neg 0 60 0 60 0 60
75 -75 0 60 0 60 0 60
150 -50 0 60 0 60 0 60
225 -25 4 56 6 54 8 52
300 Cutoff 36 24 34 26 32 28
375 +25 54 6 56 4 52 8
450 +50 60 0 60 0 60 0
525 +75 60 0 60 0 60 0
600 +100 60 0 60 0 60 0
14

[Table 1 on page 14]
Conc
(ng/mL)	% of
cutoff	Lot 1		Lot 2		Lot 3	
		Pos	Neg	Pos	Neg	Pos	Neg
0	Neg	0	60	0	60	0	60
75	-75	0	60	0	60	0	60
150	-50	0	60	0	60	0	60
225	-25	8	52	4	56	6	54
300	Cutoff	36	24	38	22	34	26
375	+25	56	4	52	8	54	6
450	+50	60	0	60	0	60	0
525	+75	60	0	60	0	60	0
600	+100	60	0	60	0	60	0

[Table 2 on page 14]
Conc
(ng/mL)	% of
cutoff	Lot 1		Lot 2		Lot 3	
		Pos	Neg	Pos	Neg	Pos	Neg
0	Neg	0	60	0	60	0	60
75	-75	0	60	0	60	0	60
150	-50	0	60	0	60	0	60
225	-25	4	56	8	52	6	54
300	Cutoff	36	24	34	26	38	22
375	+25	56	4	52	8	54	6
450	+50	60	0	60	0	60	0
525	+75	60	0	60	0	60	0
600	+100	60	0	60	0	60	0

[Table 3 on page 14]
Conc
(ng/mL)	% of
cutoff	Lot 1		Lot 2		Lot 3	
		Pos	Neg	Pos	Neg	Pos	Neg
0	Neg	0	60	0	60	0	60
75	-75	0	60	0	60	0	60
150	-50	0	60	0	60	0	60
225	-25	4	56	6	54	8	52
300	Cutoff	36	24	34	26	32	28
375	+25	54	6	56	4	52	8
450	+50	60	0	60	0	60	0
525	+75	60	0	60	0	60	0
600	+100	60	0	60	0	60	0

--- Page 15 ---
Morphine – Dipcard Format – Multi
Conc % of Lot 1 Lot 2 Lot 3
(ng/mL) cutoff Pos Neg Pos Neg Pos Neg
0 Neg 0 60 0 60 0 60
75 -75 0 60 0 60 0 60
150 -50 0 60 0 60 0 60
225 -25 4 56 8 52 6 54
300 Cutoff 36 24 38 22 34 26
375 +25 52 8 56 4 54 6
450 +50 60 0 60 0 60 0
525 +75 60 0 60 0 60 0
600 +100 60 0 60 0 60 0
Morphine – Dipcard Format – Single
Conc % of Lot 1 Lot 2 Lot 3
(ng/mL) cutoff Pos Neg Pos Neg Pos Neg
0 Neg 0 60 0 60 0 60
75 -75 0 60 0 60 0 60
150 -50 0 60 0 60 0 60
225 -25 6 54 8 52 4 56
300 Cutoff 32 28 36 24 34 26
375 +25 54 6 56 4 52 8
450 +50 60 0 60 0 60 0
525 +75 60 0 60 0 60 0
600 +100 60 0 60 0 60 0
Morphine – Cup Format – Multi
Conc % of Lot 1 Lot 2 Lot 3
(ng/mL) cutoff Pos Neg Pos Neg Pos Neg
0 Neg 0 60 0 60 0 60
75 -75 0 60 0 60 0 60
150 -50 0 60 0 60 0 60
225 -25 6 54 4 56 6 54
300 Cutoff 38 22 34 26 36 24
375 +25 52 8 54 6 56 4
450 +50 60 0 60 0 60 0
525 +75 60 0 60 0 60 0
600 +100 60 0 60 0 60 0
15

[Table 1 on page 15]
Conc
(ng/mL)	% of
cutoff	Lot 1		Lot 2		Lot 3	
		Pos	Neg	Pos	Neg	Pos	Neg
0	Neg	0	60	0	60	0	60
75	-75	0	60	0	60	0	60
150	-50	0	60	0	60	0	60
225	-25	4	56	8	52	6	54
300	Cutoff	36	24	38	22	34	26
375	+25	52	8	56	4	54	6
450	+50	60	0	60	0	60	0
525	+75	60	0	60	0	60	0
600	+100	60	0	60	0	60	0

[Table 2 on page 15]
Conc
(ng/mL)	% of
cutoff	Lot 1		Lot 2		Lot 3	
		Pos	Neg	Pos	Neg	Pos	Neg
0	Neg	0	60	0	60	0	60
75	-75	0	60	0	60	0	60
150	-50	0	60	0	60	0	60
225	-25	6	54	8	52	4	56
300	Cutoff	32	28	36	24	34	26
375	+25	54	6	56	4	52	8
450	+50	60	0	60	0	60	0
525	+75	60	0	60	0	60	0
600	+100	60	0	60	0	60	0

[Table 3 on page 15]
Conc
(ng/mL)	% of
cutoff	Lot 1		Lot 2		Lot 3	
		Pos	Neg	Pos	Neg	Pos	Neg
0	Neg	0	60	0	60	0	60
75	-75	0	60	0	60	0	60
150	-50	0	60	0	60	0	60
225	-25	6	54	4	56	6	54
300	Cutoff	38	22	34	26	36	24
375	+25	52	8	54	6	56	4
450	+50	60	0	60	0	60	0
525	+75	60	0	60	0	60	0
600	+100	60	0	60	0	60	0

--- Page 16 ---
Morphine – Cup Format – Single
Conc % of Lot 1 Lot 2 Lot 3
(ng/mL) cutoff Pos Neg Pos Neg Pos Neg
0 Neg 0 60 0 60 0 60
75 -75 0 60 0 60 0 60
150 -50 0 60 0 60 0 60
225 -25 6 54 4 56 8 52
300 Cutoff 36 24 36 24 34 26
375 +25 56 4 54 6 52 8
450 +50 60 0 60 0 60 0
525 +75 60 0 60 0 60 0
600 +100 60 0 60 0 60 0
Propoxyphene – Dipcard Format – Multi
Conc % of Lot 1 Lot 2 Lot 3
(ng/mL) cutoff Pos Neg Pos Neg Pos Neg
0 Neg 0 60 0 60 0 60
75 -75 0 60 0 60 0 60
150 -50 0 60 0 60 0 60
225 -25 6 54 8 52 4 56
300 Cutoff 36 24 34 26 38 22
375 +25 56 4 52 8 54 6
450 +50 60 0 60 0 60 0
525 +75 60 0 60 0 60 0
600 +100 60 0 60 0 60 0
Propoxyphene – Dipcard Format – Single
Conc % of Lot 1 Lot 2 Lot 3
(ng/mL) cutoff Pos Neg Pos Neg Pos Neg
0 Neg 0 60 0 60 0 60
75 -75 0 60 0 60 0 60
150 -50 0 60 0 60 0 60
225 -25 4 56 6 54 8 52
300 Cutoff 34 26 32 28 36 24
375 +25 52 8 56 4 54 6
450 +50 60 0 60 0 60 0
525 +75 60 0 60 0 60 0
600 +100 60 0 60 0 60 0
16

[Table 1 on page 16]
Conc
(ng/mL)	% of
cutoff	Lot 1		Lot 2		Lot 3	
		Pos	Neg	Pos	Neg	Pos	Neg
0	Neg	0	60	0	60	0	60
75	-75	0	60	0	60	0	60
150	-50	0	60	0	60	0	60
225	-25	6	54	4	56	8	52
300	Cutoff	36	24	36	24	34	26
375	+25	56	4	54	6	52	8
450	+50	60	0	60	0	60	0
525	+75	60	0	60	0	60	0
600	+100	60	0	60	0	60	0

[Table 2 on page 16]
Conc
(ng/mL)	% of
cutoff	Lot 1		Lot 2		Lot 3	
		Pos	Neg	Pos	Neg	Pos	Neg
0	Neg	0	60	0	60	0	60
75	-75	0	60	0	60	0	60
150	-50	0	60	0	60	0	60
225	-25	6	54	8	52	4	56
300	Cutoff	36	24	34	26	38	22
375	+25	56	4	52	8	54	6
450	+50	60	0	60	0	60	0
525	+75	60	0	60	0	60	0
600	+100	60	0	60	0	60	0

[Table 3 on page 16]
Conc
(ng/mL)	% of
cutoff	Lot 1		Lot 2		Lot 3	
		Pos	Neg	Pos	Neg	Pos	Neg
0	Neg	0	60	0	60	0	60
75	-75	0	60	0	60	0	60
150	-50	0	60	0	60	0	60
225	-25	4	56	6	54	8	52
300	Cutoff	34	26	32	28	36	24
375	+25	52	8	56	4	54	6
450	+50	60	0	60	0	60	0
525	+75	60	0	60	0	60	0
600	+100	60	0	60	0	60	0

--- Page 17 ---
Propoxyphene – Cup Format – Multi
Conc % of Lot 1 Lot 2 Lot 3
(ng/mL) cutoff Pos Neg Pos Neg Pos Neg
0 Neg 0 60 0 60 0 60
75 -75 0 60 0 60 0 60
150 -50 0 60 0 60 0 60
225 -25 8 52 4 56 6 54
300 Cutoff 34 26 36 24 32 28
375 +25 52 8 56 4 54 6
450 +50 60 0 60 0 60 0
525 +75 60 0 60 0 60 0
600 +100 60 0 60 0 60 0
Propoxyphene – Cup Format – Single
Conc % of Lot 1 Lot 2 Lot 3
(ng/mL) cutoff Pos Neg Pos Neg Pos Neg
0 Neg 0 60 0 60 0 60
75 -75 0 60 0 60 0 60
150 -50 0 60 0 60 0 60
225 -25 8 52 6 54 4 56
300 Cutoff 32 28 36 24 34 26
375 +25 56 4 54 6 54 6
450 +50 60 0 60 0 60 0
525 +75 60 0 60 0 60 0
600 +100 60 0 60 0 60 0
TCA – Dipcard Format – Multi
Conc % of Lot 1 Lot 2 Lot 3
(ng/mL) cutoff Pos Neg Pos Neg Pos Neg
0 Neg 0 60 0 60 0 60
250 -75 0 60 0 60 0 60
500 -50 0 60 0 60 0 60
750 -25 6 54 6 54 4 56
1000 Cutoff 38 22 34 26 34 26
1250 +25 52 8 54 6 56 4
1500 +50 60 0 60 0 60 0
1750 +75 60 0 60 0 60 0
2000 +100 60 0 60 0 60 0
17

[Table 1 on page 17]
Conc
(ng/mL)	% of
cutoff	Lot 1		Lot 2		Lot 3	
		Pos	Neg	Pos	Neg	Pos	Neg
0	Neg	0	60	0	60	0	60
75	-75	0	60	0	60	0	60
150	-50	0	60	0	60	0	60
225	-25	8	52	4	56	6	54
300	Cutoff	34	26	36	24	32	28
375	+25	52	8	56	4	54	6
450	+50	60	0	60	0	60	0
525	+75	60	0	60	0	60	0
600	+100	60	0	60	0	60	0

[Table 2 on page 17]
Conc
(ng/mL)	% of
cutoff	Lot 1		Lot 2		Lot 3	
		Pos	Neg	Pos	Neg	Pos	Neg
0	Neg	0	60	0	60	0	60
75	-75	0	60	0	60	0	60
150	-50	0	60	0	60	0	60
225	-25	8	52	6	54	4	56
300	Cutoff	32	28	36	24	34	26
375	+25	56	4	54	6	54	6
450	+50	60	0	60	0	60	0
525	+75	60	0	60	0	60	0
600	+100	60	0	60	0	60	0

[Table 3 on page 17]
Conc
(ng/mL)	% of
cutoff	Lot 1		Lot 2		Lot 3	
		Pos	Neg	Pos	Neg	Pos	Neg
0	Neg	0	60	0	60	0	60
250	-75	0	60	0	60	0	60
500	-50	0	60	0	60	0	60
750	-25	6	54	6	54	4	56
1000	Cutoff	38	22	34	26	34	26
1250	+25	52	8	54	6	56	4
1500	+50	60	0	60	0	60	0
1750	+75	60	0	60	0	60	0
2000	+100	60	0	60	0	60	0

--- Page 18 ---
TCA – Dipcard Format – Single
Conc % of Lot 1 Lot 2 Lot 3
(ng/mL) cutoff Pos Neg Pos Neg Pos Neg
0 Neg 0 60 0 60 0 60
250 -75 0 60 0 60 0 60
500 -50 0 60 0 60 0 60
750 -25 8 52 6 54 4 56
1000 Cutoff 38 22 36 24 34 26
1250 +25 56 4 54 6 52 8
1500 +50 60 0 60 0 60 0
1750 +75 60 0 60 0 60 0
2000 +100 60 0 60 0 60 0
TCA – Cup Format – Multi
Conc % of Lot 1 Lot 2 Lot 3
(ng/mL) cutoff Pos Neg Pos Neg Pos Neg
0 Neg 0 60 0 60 0 60
250 -75 0 60 0 60 0 60
500 -50 0 60 0 60 0 60
750 -25 6 54 8 52 6 54
1000 Cutoff 36 24 38 22 34 26
1250 +25 54 6 56 4 52 8
1500 +50 60 0 60 0 60 0
1750 +75 60 0 60 0 60 0
2000 +100 60 0 60 0 60 0
TCA – Cup Format – Single
Conc % of Lot 1 Lot 2 Lot 3
(ng/mL) cutoff Pos Neg Pos Neg Pos Neg
0 Neg 0 60 0 60 0 60
250 -75 0 60 0 60 0 60
500 -50 0 60 0 60 0 60
750 -25 4 56 8 52 6 54
1000 Cutoff 36 24 34 26 34 26
1250 +25 54 6 52 8 56 4
1500 +50 60 0 60 0 60 0
1750 +75 60 0 60 0 60 0
2000 +100 60 0 60 0 60 0
b. Linearity/assay reportable range:
Not applicable. The assays are intended for qualitative use.
18

[Table 1 on page 18]
Conc
(ng/mL)	% of
cutoff	Lot 1		Lot 2		Lot 3	
		Pos	Neg	Pos	Neg	Pos	Neg
0	Neg	0	60	0	60	0	60
250	-75	0	60	0	60	0	60
500	-50	0	60	0	60	0	60
750	-25	8	52	6	54	4	56
1000	Cutoff	38	22	36	24	34	26
1250	+25	56	4	54	6	52	8
1500	+50	60	0	60	0	60	0
1750	+75	60	0	60	0	60	0
2000	+100	60	0	60	0	60	0

[Table 2 on page 18]
Conc
(ng/mL)	% of
cutoff	Lot 1		Lot 2		Lot 3	
		Pos	Neg	Pos	Neg	Pos	Neg
0	Neg	0	60	0	60	0	60
250	-75	0	60	0	60	0	60
500	-50	0	60	0	60	0	60
750	-25	6	54	8	52	6	54
1000	Cutoff	36	24	38	22	34	26
1250	+25	54	6	56	4	52	8
1500	+50	60	0	60	0	60	0
1750	+75	60	0	60	0	60	0
2000	+100	60	0	60	0	60	0

[Table 3 on page 18]
Conc
(ng/mL)	% of
cutoff	Lot 1		Lot 2		Lot 3	
		Pos	Neg	Pos	Neg	Pos	Neg
0	Neg	0	60	0	60	0	60
250	-75	0	60	0	60	0	60
500	-50	0	60	0	60	0	60
750	-25	4	56	8	52	6	54
1000	Cutoff	36	24	34	26	34	26
1250	+25	54	6	52	8	56	4
1500	+50	60	0	60	0	60	0
1750	+75	60	0	60	0	60	0
2000	+100	60	0	60	0	60	0

--- Page 19 ---
c. Traceability, Stability, Expected values (controls, calibrators, or methods):
External control standards are not supplied with this device; labeling states where
external control materials can be obtained.
Accelerated and real time studies have been conducted for The One Step
Single/Multidrug Test Cup and the One Step Single/Multi-drug Test Dipcard devices.
Protocols and acceptance criteria were reviewed and found to be acceptable. The
information supports the following expiration date for the unopened (shelf-life)
stability: 24 months under 4 - 30° C for both the Test Cup and Dipcard formats.
d. Detection limit:
Not applicable. The assays are intended for qualitative use.
e. Analytical specificity:
Cross reactivity with structurally similar compounds was tested for each device
format. Each compound was spiked into drug-free urine to a final concentration of
100 µg/mL. Each sample was tested in 5 replicates. If any positive results were
observed, samples were diluted down to the lowest concentration that produced a
positive result. Results were as follows:
Concentration % Cross-
Compound tested
(ng/mL) reactivity
Buprenorphine 10 100
Norbuprenorphine 20 50
Buprenorphine
Buprenorphine 3-D-
15 66.7
glucuronide
Norbuprenorphine3-D-
200 5
glucuronide
Concentration % Cross-
Compound tested
(ng/mL) reactivity
EDDP
EDDP 300 100
Methadone 100,000 0
19

[Table 1 on page 19]
Buprenorphine	Compound tested		Concentration			% Cross-	
			(ng/mL)			reactivity	
	Buprenorphine	10			100		
	Norbuprenorphine	20			50		
	Buprenorphine 3-D-
glucuronide	15			66.7		
	Norbuprenorphine3-D-
glucuronide	200			5		

[Table 2 on page 19]
EDDP	Compound tested		Concentration			% Cross-	
			(ng/mL)			reactivity	
	EDDP	300			100		
	Methadone	100,000			0		

--- Page 20 ---
Concentration % Cross-
Compound tested
(ng/mL) reactivity
Morphine 300 100
Codeine 300 100
Hydrocodone 2000 15
Hydromorphone 1500 20
6-Monoacetyl
750 40
morphine (6-MAM)
Morphine
Morphine 3-β-D-
300 100
glucuronide
Ethylmorphine 3500 8.6
Heroin 300 100
Levorphanol 5000 6.0
Norcodeine 7500 4.0
Oxycodone 100,000 0.3
Thebain 8000 3.8
Concentration % Cross-
Compound tested
(ng/mL) reactivity
d-Propoxyphene 300 100
Propoxyphene
d-Norpropoxyphene 300 100
Concentration % Cross-
Compound tested
(ng/mL) reactivity
Nortriptyline 1000 100
Nordoxepin 1000 100
Trimipramine 5000 20
Promazine 3000 33.3
Tricyclic Antidepressants
Desipramine 1000 100
Imipramine 1000 100
Chomipramine 12500 8
Doxepin 2000 50
Maprotiline 2000 50
Amitriptyline 1000 100
20

[Table 1 on page 20]
Morphine	Compound tested		Concentration			% Cross-	
			(ng/mL)			reactivity	
	Morphine	300			100		
	Codeine	300			100		
	Hydrocodone	2000			15		
	Hydromorphone	1500			20		
	6-Monoacetyl
morphine (6-MAM)	750			40		
	Morphine 3-β-D-
glucuronide	300			100		
	Ethylmorphine	3500			8.6		
	Heroin	300			100		
	Levorphanol	5000			6.0		
	Norcodeine	7500			4.0		
	Oxycodone	100,000			0.3		
	Thebain	8000			3.8		

[Table 2 on page 20]
Propoxyphene	Compound tested		Concentration			% Cross-	
			(ng/mL)			reactivity	
	d-Propoxyphene	300			100		
	d-Norpropoxyphene	300			100		

[Table 3 on page 20]
Tricyclic Antidepressants	Compound tested		Concentration			% Cross-	
			(ng/mL)			reactivity	
	Nortriptyline	1000			100		
	Nordoxepin	1000			100		
	Trimipramine	5000			20		
	Promazine	3000			33.3		
	Desipramine	1000			100		
	Imipramine	1000			100		
	Chomipramine	12500			8		
	Doxepin	2000			50		
	Maprotiline	2000			50		
	Amitriptyline	1000			100		

--- Page 21 ---
Interference Study:
The following structurally unrelated compounds were spiked at 100 μg/mL into
samples at -50% and +50% of the cutoff for each analyte. Each test format was
evaluated. None of these compounds caused any interference at the concentration
tested.
Acetaminophen Digoxin Nadolol Tetrahydrozoline
Acetophenetidin Diphenhydramine Nalidixic acid Thiamine
Amoxicillin Ephedrine Naproxen Thioridazine
Ampicillin β-Estradiol Niacinamide d, l-Thyroxine
Aspirin Estrone-3-sulfate Nicotine Tolbutamine
Ethyl-p-
Atenolol Nifedipine Tolbutamide
aminobenzoate
Atorvastatin Erythromycin Norethindrone Trifluoperazine
Azlocillin Fenoprofen Noscapine Tryptamine
Benzylpenicillin Flucloxacillin d,l-Octopamine Uric acid
Benzoic acid Fluoxetine Oxalic acid Verapamil
Benzilic acid Furosemide Oxolinic acid Zomepirac
Bilirubin Gentisic acid Oxymetazoline
Benzydamine Hemoglobin Oxytetracycline
Caffeine Hydralazine Papaverine
Carbamezepine Hydrochlorothiazide Penicillin-G
Cephalexin Hydrocortisone Pentazocine
o-Hydroxyhippuric
Chloralhydrate Perphenazine
acid
Chloramphenicol p-Hydroxytyramine Phenelzine
Chlorothiazide Ibuprofen Prednisolone
Chlorpheniramine Indomethacin Prednisone
d,l-Chlorpromazine Iproniazid Promethazine
Cholesterol d,l-Isoproterenol d,l-Propanolol
Clonidine Isoxsuprine d-Pseudoephedrine
Cimetidine Ketamine Quinacrine
Citalopram Ketoprofen Quinine
Cortisone Labetalol Quindine
Creatinine Lisinopril Ranitidine
Deoxycorticosterone Loperamide Salicylic acid
Dexamethasone Meperidine Serotonin
Dextromethorphan Meprobamate Sulfamethazine
Diclofenac Methoxyphenamine Sulindac
Diflunisal Methylphenidate Tetracycline
21

[Table 1 on page 21]
Acetaminophen	Digoxin	Nadolol	Tetrahydrozoline
Acetophenetidin	Diphenhydramine	Nalidixic acid	Thiamine
Amoxicillin	Ephedrine	Naproxen	Thioridazine
Ampicillin	β-Estradiol	Niacinamide	d, l-Thyroxine
Aspirin	Estrone-3-sulfate	Nicotine	Tolbutamine
Atenolol	Ethyl-p-
aminobenzoate	Nifedipine	Tolbutamide
Atorvastatin	Erythromycin	Norethindrone	Trifluoperazine
Azlocillin	Fenoprofen	Noscapine	Tryptamine
Benzylpenicillin	Flucloxacillin	d,l-Octopamine	Uric acid
Benzoic acid	Fluoxetine	Oxalic acid	Verapamil
Benzilic acid	Furosemide	Oxolinic acid	Zomepirac
Bilirubin	Gentisic acid	Oxymetazoline	
Benzydamine	Hemoglobin	Oxytetracycline	
Caffeine	Hydralazine	Papaverine	
Carbamezepine	Hydrochlorothiazide	Penicillin-G	
Cephalexin	Hydrocortisone	Pentazocine	
Chloralhydrate	o-Hydroxyhippuric
acid	Perphenazine	
Chloramphenicol	p-Hydroxytyramine	Phenelzine	
Chlorothiazide	Ibuprofen	Prednisolone	
Chlorpheniramine	Indomethacin	Prednisone	
d,l-Chlorpromazine	Iproniazid	Promethazine	
Cholesterol	d,l-Isoproterenol	d,l-Propanolol	
Clonidine	Isoxsuprine	d-Pseudoephedrine	
Cimetidine	Ketamine	Quinacrine	
Citalopram	Ketoprofen	Quinine	
Cortisone	Labetalol	Quindine	
Creatinine	Lisinopril	Ranitidine	
Deoxycorticosterone	Loperamide	Salicylic acid	
Dexamethasone	Meperidine	Serotonin	
Dextromethorphan	Meprobamate	Sulfamethazine	
Diclofenac	Methoxyphenamine	Sulindac	
Diflunisal	Methylphenidate	Tetracycline	

--- Page 22 ---
Each device was also evaluated for interference from pH. Drug-free urine was
adjusted to ± 50% cutoffs which were confirmed by GC/MS or LC/MS. Each test
format was used for the study. The pH was tested at 3, 4, 5, 6, 7, 8, and 9. No
interference from pH was observed.
Each device was evaluated for interference from specific gravity. Drug-free urine was
adjusted to ± 50% cutoffs which were confirmed by GC/MS or LC/MS. Each test
format was used for the study. Specific gravity was tested at 1.003, 1.010, 1.020,
1.030, and 1.040. No interference from specific gravity was observed.
f. Assay cut-off:
The cut-off characterization study results can be found in the precision section
1.M.1.a above.
2. Comparison studies:
a. Method comparison with predicate device:
Eighty clinical urine samples collected from several hospitals and a drug relief
reformatory. All samples were unaltered clinical specimens and the concentrations
were confirmed by GC/MS, LC/MS, or HPLC. Each sample was split between two
individuals. All aliquots were blindly labeled by a nonparticipant, and randomized
prior to testing such that a different sample was used each time testing was
performed. Testing was conducted by four nurses at two POC sites.
Buprenorphine - Dipcard Format - Multi
Near Cutoff Near Cutoff
Negative Positive High Positive
(Between 50% (Between the (greater than
Candidate
Negative below the cutoff and 50% above the
device result
cutoff and the 50% above the cutoff
cutoff cutoff concentration)
concentration) concentration)
Pos 0 *1 5 35
Neg 35 4 0 0
*Analysis of Discordant Results – LC/MS concentration 7.8 ng/mL buprenorphine
22

[Table 1 on page 22]
Candidate
device result	Negative	Near Cutoff
Negative
(Between 50%
below the
cutoff and the
cutoff
concentration)	Near Cutoff
Positive
(Between the
cutoff and
50% above the
cutoff
concentration)	High Positive
(greater than
50% above the
cutoff
concentration)
Pos	0	*1	5	35
Neg	35	4	0	0

--- Page 23 ---
Buprenorphine - Dipcard Format - Single
Near Cutoff Near Cutoff
Negative Positive High Positive
(Between 50% (Between the (greater than
Candidate
Negative below the cutoff and 50% above the
device result
cutoff and the 50% above the cutoff
cutoff cutoff concentration)
concentration) concentration)
Pos 0 *1 5 35
Neg 35 4 0 0
*Analysis of Discordant Results – LC/MS concentration 7.8 ng/mL buprenorphine
Buprenorphine - Cup Format - Multiple
Near Cutoff Near Cutoff
Negative Positive High Positive
(Between 50% (Between the (greater than
Candidate
Negative below the cutoff and 50% above the
device result
cutoff and the 50% above the cutoff
cutoff cutoff concentration)
concentration) concentration)
Pos 0 *1 5 35
Neg 35 4 0 0
*Analysis of Discordant Results – LC/MS concentration 7.8 ng/mL buprenorphine
Buprenorphine - Cup Format - Single
Near Cutoff Near Cutoff
Negative Positive High Positive
(Between 50% (Between the (greater than
Candidate
Negative below the cutoff and 50% above the
device result
cutoff and the 50% above the cutoff
cutoff cutoff concentration)
concentration) concentration)
Pos 0 *1 5 35
Neg 35 4 0 0
*Analysis of Discordant Results – LC/MS concentration 7.8 ng/mL buprenorphine
23

[Table 1 on page 23]
Candidate
device result	Negative	Near Cutoff
Negative
(Between 50%
below the
cutoff and the
cutoff
concentration)	Near Cutoff
Positive
(Between the
cutoff and
50% above the
cutoff
concentration)	High Positive
(greater than
50% above the
cutoff
concentration)
Pos	0	*1	5	35
Neg	35	4	0	0

[Table 2 on page 23]
Candidate
device result	Negative	Near Cutoff
Negative
(Between 50%
below the
cutoff and the
cutoff
concentration)	Near Cutoff
Positive
(Between the
cutoff and
50% above the
cutoff
concentration)	High Positive
(greater than
50% above the
cutoff
concentration)
Pos	0	*1	5	35
Neg	35	4	0	0

[Table 3 on page 23]
Candidate
device result	Negative	Near Cutoff
Negative
(Between 50%
below the
cutoff and the
cutoff
concentration)	Near Cutoff
Positive
(Between the
cutoff and
50% above the
cutoff
concentration)	High Positive
(greater than
50% above the
cutoff
concentration)
Pos	0	*1	5	35
Neg	35	4	0	0

--- Page 24 ---
EDDP - Dipcard Format - Multiple
Near Cutoff Near Cutoff
Negative Positive High Positive
(Between 50% (Between the (greater than
Candidate
Negative below the cutoff and 50% above the
device result
cutoff and the 50% above the cutoff
cutoff cutoff concentration)
concentration) concentration)
Pos 0 *1 7 33
Neg 34 5 0 0
*Analysis of Discordant Results – GC/MS concentration 285 ng/mL EDDP
EDDP - Dipcard Format - Single
Near Cutoff Near Cutoff
Negative Positive High Positive
(Between 50% (Between the (greater than
Candidate
Negative below the cutoff and 50% above the
device result
cutoff and the 50% above the cutoff
cutoff cutoff concentration)
concentration) concentration)
Pos 0 *1 7 33
Neg 34 5 0 0
*Analysis of Discordant Results – GC/MS concentration 285 ng/mL EDDP
EDDP - Cup Format - Multi
Near Cutoff Near Cutoff
Negative Positive High Positive
(Between 50% (Between the (greater than
Candidate
Negative below the cutoff and 50% above the
device result
cutoff and the 50% above the cutoff
cutoff cutoff concentration)
concentration) concentration)
Pos 0 *1 7 33
Neg 34 5 0 0
*Analysis of Discordant Results – GC/MS concentration 285 ng/mL EDDP
24

[Table 1 on page 24]
Candidate
device result	Negative	Near Cutoff
Negative
(Between 50%
below the
cutoff and the
cutoff
concentration)	Near Cutoff
Positive
(Between the
cutoff and
50% above the
cutoff
concentration)	High Positive
(greater than
50% above the
cutoff
concentration)
Pos	0	*1	7	33
Neg	34	5	0	0

[Table 2 on page 24]
Candidate
device result	Negative	Near Cutoff
Negative
(Between 50%
below the
cutoff and the
cutoff
concentration)	Near Cutoff
Positive
(Between the
cutoff and
50% above the
cutoff
concentration)	High Positive
(greater than
50% above the
cutoff
concentration)
Pos	0	*1	7	33
Neg	34	5	0	0

[Table 3 on page 24]
Candidate
device result	Negative	Near Cutoff
Negative
(Between 50%
below the
cutoff and the
cutoff
concentration)	Near Cutoff
Positive
(Between the
cutoff and
50% above the
cutoff
concentration)	High Positive
(greater than
50% above the
cutoff
concentration)
Pos	0	*1	7	33
Neg	34	5	0	0

--- Page 25 ---
EDDP - Cup Format - Single
Near Cutoff Near Cutoff
Negative Positive High Positive
(Between 50% (Between the (greater than
Candidate
Negative below the cutoff and 50% above the
device result
cutoff and the 50% above the cutoff
cutoff cutoff concentration)
concentration) concentration)
Pos 0 *1 7 33
Neg 34 5 0 0
*Analysis of Discordant Results – GC/MS concentration 285 ng/mL EDDP
Morphine - Dipcard Format - Multi
Near Cutoff Near Cutoff
Negative Positive High Positive
(Between 50% (Between the (greater than
Candidate
Negative below the cutoff and 50% above the
device result
cutoff and the 50% above the cutoff
cutoff cutoff concentration)
concentration) concentration)
Pos 0 *1 5 35
Neg 33 6 0 0
*Analysis of Discordant Results – GC/MS concentration 275 ng/mL Morphine
Morphine - Dipcard Format - Single
Near Cutoff Near Cutoff
Negative Positive High Positive
(Between 50% (Between the (greater than
Candidate
Negative below the cutoff and 50% above the
device result
cutoff and the 50% above the cutoff
cutoff cutoff concentration)
concentration) concentration)
Pos 0 *1 5 35
Neg 33 6 0 0
*Analysis of Discordant Results – GC/MS concentration 275 ng/mL Morphine
25

[Table 1 on page 25]
Candidate
device result	Negative	Near Cutoff
Negative
(Between 50%
below the
cutoff and the
cutoff
concentration)	Near Cutoff
Positive
(Between the
cutoff and
50% above the
cutoff
concentration)	High Positive
(greater than
50% above the
cutoff
concentration)
Pos	0	*1	7	33
Neg	34	5	0	0

[Table 2 on page 25]
Candidate
device result	Negative	Near Cutoff
Negative
(Between 50%
below the
cutoff and the
cutoff
concentration)	Near Cutoff
Positive
(Between the
cutoff and
50% above the
cutoff
concentration)	High Positive
(greater than
50% above the
cutoff
concentration)
Pos	0	*1	5	35
Neg	33	6	0	0

[Table 3 on page 25]
Candidate
device result	Negative	Near Cutoff
Negative
(Between 50%
below the
cutoff and the
cutoff
concentration)	Near Cutoff
Positive
(Between the
cutoff and
50% above the
cutoff
concentration)	High Positive
(greater than
50% above the
cutoff
concentration)
Pos	0	*1	5	35
Neg	33	6	0	0

--- Page 26 ---
Morphine - Cup Format - multi
Near Cutoff Near Cutoff
Negative Positive High Positive
(Between 50% (Between the (greater than
Candidate
Negative below the cutoff and 50% above the
device result
cutoff and the 50% above the cutoff
cutoff cutoff concentration)
concentration) concentration)
Pos 0 1 5 35
Neg 33 6 0 0
*Analysis of Discordant Results – GC/MS concentration 275 ng/mL Morphine
Morphine - Cup Format - single
Near Cutoff Near Cutoff
Negative Positive High Positive
(Between 50% (Between the (greater than
Candidate
Negative below the cutoff and 50% above the
device result
cutoff and the 50% above the cutoff
cutoff cutoff concentration)
concentration) concentration)
Pos 0 1 5 35
Neg 33 6 0 0
*Analysis of Discordant Results – GC/MS concentration 275 ng/mL Morphine
Propoxyphene - Dipcard Format - multi
Near Cutoff Near Cutoff
Negative Positive High Positive
(Between 50% (Between the (greater than
Candidate
Negative below the cutoff and 50% above the
device result
cutoff and the 50% above the cutoff
cutoff cutoff concentration)
concentration) concentration)
Pos 0 *1 6 34
Neg 34 5 0 0
*Analysis of Discordant Results – GC/MS concentration 269 ng/mL Propoxyphene
26

[Table 1 on page 26]
Candidate
device result	Negative	Near Cutoff
Negative
(Between 50%
below the
cutoff and the
cutoff
concentration)	Near Cutoff
Positive
(Between the
cutoff and
50% above the
cutoff
concentration)	High Positive
(greater than
50% above the
cutoff
concentration)
Pos	0	1	5	35
Neg	33	6	0	0

[Table 2 on page 26]
Candidate
device result	Negative	Near Cutoff
Negative
(Between 50%
below the
cutoff and the
cutoff
concentration)	Near Cutoff
Positive
(Between the
cutoff and
50% above the
cutoff
concentration)	High Positive
(greater than
50% above the
cutoff
concentration)
Pos	0	1	5	35
Neg	33	6	0	0

[Table 3 on page 26]
Candidate
device result	Negative	Near Cutoff
Negative
(Between 50%
below the
cutoff and the
cutoff
concentration)	Near Cutoff
Positive
(Between the
cutoff and
50% above the
cutoff
concentration)	High Positive
(greater than
50% above the
cutoff
concentration)
Pos	0	*1	6	34
Neg	34	5	0	0

--- Page 27 ---
Propoxyphene - Dipcard Format - single
Near Cutoff Near Cutoff
Negative Positive High Positive
(Between 50% (Between the (greater than
Candidate
Negative below the cutoff and 50% above the
device result
cutoff and the 50% above the cutoff
cutoff cutoff concentration)
concentration) concentration)
Pos 0 *1 6 34
Neg 34 5 0 0
*Analysis of Discordant Results – GC/MS concentration 269 ng/mL Propoxyphene
Propoxyphene - Cup Format - multi
Near Cutoff Near Cutoff
Negative Positive High Positive
(Between 50% (Between the (greater than
Candidate
Negative below the cutoff and 50% above the
device result
cutoff and the 50% above the cutoff
cutoff cutoff concentration)
concentration) concentration)
Pos 0 *1 6 34
Neg 34 5 0 0
*Analysis of Discordant Results – GC/MS concentration 269 ng/mL Propoxyphene
Propoxyphene - Cup Format - single
Near Cutoff Near Cutoff
Negative Positive High Positive
(Between 50% (Between the (greater than
Candidate
Negative below the cutoff and 50% above the
device result
cutoff and the 50% above the cutoff
cutoff cutoff concentration)
concentration) concentration)
Pos 0 *1 6 34
Neg 34 5 0 0
*Analysis of Discordant Results – GC/MS concentration 269 ng/mL Propoxyphene
27

[Table 1 on page 27]
Candidate
device result	Negative	Near Cutoff
Negative
(Between 50%
below the
cutoff and the
cutoff
concentration)	Near Cutoff
Positive
(Between the
cutoff and
50% above the
cutoff
concentration)	High Positive
(greater than
50% above the
cutoff
concentration)
Pos	0	*1	6	34
Neg	34	5	0	0

[Table 2 on page 27]
Candidate
device result	Negative	Near Cutoff
Negative
(Between 50%
below the
cutoff and the
cutoff
concentration)	Near Cutoff
Positive
(Between the
cutoff and
50% above the
cutoff
concentration)	High Positive
(greater than
50% above the
cutoff
concentration)
Pos	0	*1	6	34
Neg	34	5	0	0

[Table 3 on page 27]
Candidate
device result	Negative	Near Cutoff
Negative
(Between 50%
below the
cutoff and the
cutoff
concentration)	Near Cutoff
Positive
(Between the
cutoff and
50% above the
cutoff
concentration)	High Positive
(greater than
50% above the
cutoff
concentration)
Pos	0	*1	6	34
Neg	34	5	0	0

--- Page 28 ---
TCA - Dipcard Format - multi
Near Cutoff Near Cutoff
Negative Positive High Positive
(Between 50% (Between the (greater than
Candidate
Negative below the cutoff and 50% above the
device result
cutoff and the 50% above the cutoff
cutoff cutoff concentration)
concentration) concentration)
Pos 0 0 5 34
Neg 35 5 *1 0
*Analysis of Discordant Results – HPLC concentration 1138 ng/mL Nortriptyline
TCA - Dipcard Format - single
Near Cutoff Near Cutoff
Negative Positive High Positive
(Between 50% (Between the (greater than
Candidate
Negative below the cutoff and 50% above the
device result
cutoff and the 50% above the cutoff
cutoff cutoff concentration)
concentration) concentration)
Pos 0 0 5 34
Neg 35 5 *1 0
*Analysis of Discordant Results – HPLC concentration 1138 ng/mL Nortriptyline
TCA - Cup Format - Multi
Near Cutoff Near Cutoff
Negative Positive High Positive
(Between 50% (Between the (greater than
Candidate
Negative below the cutoff and 50% above the
device result
cutoff and the 50% above the cutoff
cutoff cutoff concentration)
concentration) concentration)
Pos 0 0 5 34
Neg 35 5 *1 0
*Analysis of Discordant Results – HPLC concentration 1138 ng/mL Nortriptyline
28

[Table 1 on page 28]
Candidate
device result	Negative	Near Cutoff
Negative
(Between 50%
below the
cutoff and the
cutoff
concentration)	Near Cutoff
Positive
(Between the
cutoff and
50% above the
cutoff
concentration)	High Positive
(greater than
50% above the
cutoff
concentration)
Pos	0	0	5	34
Neg	35	5	*1	0

[Table 2 on page 28]
Candidate
device result	Negative	Near Cutoff
Negative
(Between 50%
below the
cutoff and the
cutoff
concentration)	Near Cutoff
Positive
(Between the
cutoff and
50% above the
cutoff
concentration)	High Positive
(greater than
50% above the
cutoff
concentration)
Pos	0	0	5	34
Neg	35	5	*1	0

[Table 3 on page 28]
Candidate
device result	Negative	Near Cutoff
Negative
(Between 50%
below the
cutoff and the
cutoff
concentration)	Near Cutoff
Positive
(Between the
cutoff and
50% above the
cutoff
concentration)	High Positive
(greater than
50% above the
cutoff
concentration)
Pos	0	0	5	34
Neg	35	5	*1	0

--- Page 29 ---
TCA - Cup Format - Single
Near Cutoff Near Cutoff
Negative Positive High Positive
(Between 50% (Between the (greater than
Candidate
Negative below the cutoff and 50% above the
device result
cutoff and the 50% above the cutoff
cutoff cutoff concentration)
concentration) concentration)
Pos 0 0 5 34
Neg 35 5 *1 0
*Analysis of Discordant Results – HPLC concentration 1138 ng/mL Nortriptyline
b. Matrix comparison:
Not applicable. The assay is intended to be used with urine samples only.
3. Clinical studies:
a. Clinical Sensitivity:
Not applicable.
b. Clinical specificity:
Not applicable.
c. Other clinical supportive data (when a. and b. are not applicable):
Consumer study:
Three hundred and sixty (360) lay users were divided into two groups to test the
multi-version of the test devices. One group tested with the Dipcard format, and the
other group tested with the Cup format. Each lay user was provided with the package
insert (in English), one blind labeled sample, and a device. Results of the lay user
study are presented below.
Buprenorphine
Conc % of Dipcard Cup
n
(ng/mL) cutoff
Pos Neg Pos Neg
0 Neg 60 0 60 0 60
5 -50% 60 0 60 0 60
7.5 -25% 60 7 53 8 52
12.5 +25% 60 55 5 53 7
15 +50% 60 57 3 58 2
20 +100% 60 60 0 60 0
29

[Table 1 on page 29]
Candidate
device result	Negative	Near Cutoff
Negative
(Between 50%
below the
cutoff and the
cutoff
concentration)	Near Cutoff
Positive
(Between the
cutoff and
50% above the
cutoff
concentration)	High Positive
(greater than
50% above the
cutoff
concentration)
Pos	0	0	5	34
Neg	35	5	*1	0

[Table 2 on page 29]
Conc
(ng/mL)	% of
cutoff	n	Dipcard		Cup	
			Pos	Neg	Pos	Neg
0	Neg	60	0	60	0	60
5	-50%	60	0	60	0	60
7.5	-25%	60	7	53	8	52
12.5	+25%	60	55	5	53	7
15	+50%	60	57	3	58	2
20	+100%	60	60	0	60	0

--- Page 30 ---
EDDP
Conc % of Dipcard Cup
n
(ng/mL) cutoff
Pos Neg Pos Neg
0 Neg 60 0 60 0 60
150 -50% 60 0 60 0 60
225 -25% 60 6 54 5 55
375 +25% 60 57 3 52 8
450 +50% 60 60 0 58 2
600 +100% 60 60 0 60 0
Morphine
Conc % of Dipcard Cup
n
(ng/mL) cutoff
Pos Neg Pos Neg
0 Neg 60 0 60 0 60
150 -50% 60 0 60 0 60
225 -25% 60 2 58 3 57
375 +25% 60 54 6 52 8
450 +50% 60 59 1 58 2
600 +100% 60 60 0 60 0
Propoxyphene
Conc % of Dipcard Cup
n
(ng/mL) cutoff
Pos Neg Pos Neg
0 Neg 60 0 60 0 60
150 -50% 60 0 60 0 60
225 -25% 60 5 55 7 53
375 +25% 60 54 6 56 4
450 +50% 60 58 2 60 0
600 +100% 60 60 0 60 0
TCA
Conc % of Dipcard Cup
n
(ng/mL) cutoff
Pos Neg Pos Neg
0 Neg 60 0 60 0 60
500 -50% 60 0 60 0 60
750 -25% 60 3 57 4 56
1250 +25% 60 55 5 54 6
1500 +50% 60 59 1 60 0
2000 +100% 60 60 0 60 0
The original consumer study data showed some negative results in specimens containing
drug concentrations at +50% above the cutoff. A root cause analysis was conducted by the
30

[Table 1 on page 30]
Conc
(ng/mL)	% of
cutoff	n	Dipcard		Cup	
			Pos	Neg	Pos	Neg
0	Neg	60	0	60	0	60
150	-50%	60	0	60	0	60
225	-25%	60	6	54	5	55
375	+25%	60	57	3	52	8
450	+50%	60	60	0	58	2
600	+100%	60	60	0	60	0

[Table 2 on page 30]
Conc
(ng/mL)	% of
cutoff	n	Dipcard		Cup	
			Pos	Neg	Pos	Neg
0	Neg	60	0	60	0	60
150	-50%	60	0	60	0	60
225	-25%	60	2	58	3	57
375	+25%	60	54	6	52	8
450	+50%	60	59	1	58	2
600	+100%	60	60	0	60	0

[Table 3 on page 30]
Conc
(ng/mL)	% of
cutoff	n	Dipcard		Cup	
			Pos	Neg	Pos	Neg
0	Neg	60	0	60	0	60
150	-50%	60	0	60	0	60
225	-25%	60	5	55	7	53
375	+25%	60	54	6	56	4
450	+50%	60	58	2	60	0
600	+100%	60	60	0	60	0

[Table 4 on page 30]
Conc
(ng/mL)	% of
cutoff	n	Dipcard		Cup	
			Pos	Neg	Pos	Neg
0	Neg	60	0	60	0	60
500	-50%	60	0	60	0	60
750	-25%	60	3	57	4	56
1250	+25%	60	55	5	54	6
1500	+50%	60	59	1	60	0
2000	+100%	60	60	0	60	0

--- Page 31 ---
sponsor to determine the cause of these results. The root cause was identified to be
inconsistent and inadequate volume of aliquoted samples. The sponsor revised the consumer
study protocol to specify a larger sample volume per vial and supplemental consumer studies
were conducted to verify that the root cause was correctly identified. Results of the
supplemental consumer studies were as follows:
Buprenorphine
Conc % of Dipcard Cup
n
(ng/mL) cutoff
Pos Neg Pos Neg
0 Neg 60 0 60 0 60
5 -50% 60 0 60 0 60
7.5 -25% 60 4 56 6 54
12.5 +25% 60 57 3 55 5
15 +50% 60 60 0 60 0
20 +100% 60 60 0 60 0
EDDP
Conc % of Dipcard Cup
n
(ng/mL) cutoff
Pos Neg Pos Neg
0 Neg 60 0 60 0 60
150 -50% 60 0 60 0 60
225 -25% 60 5 55 4 56
375 +25% 60 54 6 57 3
450 +50% 60 60 0 60 0
600 +100% 60 60 0 60 0
Morphine
Conc % of Dipcard Cup
n
(ng/mL) cutoff
Pos Neg Pos Neg
0 Neg 60 0 60 0 60
150 -50% 60 0 60 0 60
225 -25% 60 4 56 5 55
375 +25% 60 56 4 58 2
450 +50% 60 60 0 60 0
600 +100% 60 60 0 60 0
31

[Table 1 on page 31]
Conc
(ng/mL)	% of
cutoff	n	Dipcard		Cup	
			Pos	Neg	Pos	Neg
0	Neg	60	0	60	0	60
5	-50%	60	0	60	0	60
7.5	-25%	60	4	56	6	54
12.5	+25%	60	57	3	55	5
15	+50%	60	60	0	60	0
20	+100%	60	60	0	60	0

[Table 2 on page 31]
Conc
(ng/mL)	% of
cutoff	n	Dipcard		Cup	
			Pos	Neg	Pos	Neg
0	Neg	60	0	60	0	60
150	-50%	60	0	60	0	60
225	-25%	60	5	55	4	56
375	+25%	60	54	6	57	3
450	+50%	60	60	0	60	0
600	+100%	60	60	0	60	0

[Table 3 on page 31]
Conc
(ng/mL)	% of
cutoff	n	Dipcard		Cup	
			Pos	Neg	Pos	Neg
0	Neg	60	0	60	0	60
150	-50%	60	0	60	0	60
225	-25%	60	4	56	5	55
375	+25%	60	56	4	58	2
450	+50%	60	60	0	60	0
600	+100%	60	60	0	60	0

--- Page 32 ---
Propoxyphene
Conc % of Dipcard Cup
n
(ng/mL) cutoff
Pos Neg Pos Neg
0 Neg 60 0 60 0 60
150 -50% 60 0 60 0 60
225 -25% 60 5 55 3 57
375 +25% 60 56 4 54 6
450 +50% 60 60 0 60 0
600 +100% 60 60 0 60 0
TCA
Conc % of Dipcard Cup
n
(ng/mL) cutoff
Pos Neg Pos Neg
0 Neg 60 0 60 0 60
500 -50% 60 0 60 0 60
750 -25% 60 6 54 2 58
1250 +25% 60 53 7 55 5
1500 +50% 60 60 0 60 0
2000 +100% 60 60 0 60 0
After testing, each participant was asked to fill out a questionnaire assessing ease of
use of the devices. A large majority of the respondents stated that the test was easy to
use and that the instructions were clear.
4. Clinical cut-off:
Not applicable
5. Expected values/Reference range:
Not applicable
N. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.
O. Conclusion:
The submitted information in this premarket notification is complete and supports a
substantial equivalence decision.
32

[Table 1 on page 32]
Conc
(ng/mL)	% of
cutoff	n	Dipcard		Cup	
			Pos	Neg	Pos	Neg
0	Neg	60	0	60	0	60
150	-50%	60	0	60	0	60
225	-25%	60	5	55	3	57
375	+25%	60	56	4	54	6
450	+50%	60	60	0	60	0
600	+100%	60	60	0	60	0

[Table 2 on page 32]
Conc
(ng/mL)	% of
cutoff	n	Dipcard		Cup	
			Pos	Neg	Pos	Neg
0	Neg	60	0	60	0	60
500	-50%	60	0	60	0	60
750	-25%	60	6	54	2	58
1250	+25%	60	53	7	55	5
1500	+50%	60	60	0	60	0
2000	+100%	60	60	0	60	0